Literature DB >> 6094668

Rapid covalent coupling of proteins to cell surfaces: immunological characterization of viable protein-cell conjugates.

J E Christiaansen, D Gallardo, S S Burnside, A A Nelson, D W Sears.   

Abstract

A rapid and efficient 2-step procedure is described for covalently attaching proteins to cell surfaces by using a heterobifunctional cross-linking agent, succinimidyl-4-(N-maleimidomethylcyclohexane)-1-carboxylate (SMCC). In the first step, protein is derivatized for about 30 min with a 1:1 (mole:mole) stoichiometric ratio of SMCC which creates 4-(N-maleimidomethylcyclohexane)-1-amidyl-protein (MCA-protein) covalent linkages with the primary amino groups of proteins. In the second step, cell-MCA-protein conjugates are rapidly prepared (in less than 30 min) by reacting MCA-protein with 'reduced' cells which have been pre-incubated (for about 1 h) with dithiothreitol (DTT). Stable protein-cell conjugates result from the covalent thioether linkages formed between the maleimido groups of the derivatized protein and the cell surface thiol groups created by DTT reduction. Protein-cell conjugates have been made in this way with several different proteins using several different types of cells. Such conjugates are characterized in this study by complement plus antibody-mediated cytotoxicity (CAMC) and by antibody-dependent cellular cytotoxicity (ADCC) with human effector lymphocytes. Because these protein-cell conjugates are shown to remain viable and to retain significant levels of coupled protein for at least 24 h in culture, they are potentially useful for probing various membrane-related phenomena such as the recognition of cell surface antigens by immune effector cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094668     DOI: 10.1016/0022-1759(84)90290-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma.

Authors:  A Eisenthal; S A Rosenberg
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

2.  The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model.

Authors:  Tereza Janotová; Marie Jalovecká; Marie Auerová; Ivana Švecová; Pavlína Bruzlová; Veronika Maierová; Zuzana Kumžáková; Štěpánka Cunátová; Zuzana Vlčková; Veronika Caisová; Petra Rozsypalová; Katarína Lukáčová; Nikol Vácová; Markéta Wachtlová; Jiří Salát; Jaroslava Lieskovská; Jan Kopecký; Jan Ženka
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

3.  Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.

Authors:  Veronika Caisová; Andra Vieru; Zuzana Kumžáková; Simona Glaserová; Hana Husníková; Nikol Vácová; Gabriela Krejčová; Lucie Paďouková; Ivana Jochmanová; Katherine I Wolf; Jindřich Chmelař; Jan Kopecký; Jan Ženka
Journal:  BMC Cancer       Date:  2016-12-07       Impact factor: 4.430

4.  Infusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in Mice.

Authors:  Lanfang Zhang; Yixian Guo; Chang-Qing Xia
Journal:  J Immunol Res       Date:  2015-07-14       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.